Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of doxorubicin and pemetrexed. Doxorubicin is an anthracycline antibiotic that interferes with DNA replication, while pemetrexed is an antifolate antimetabolite that inhibits multiple enzymes in folate metabolism, particularly thymidylate synthase. This combination has been studied for the treatment of advanced breast cancer.
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on doxorubicin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + pemetrexed.